Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lux Biosciences has reported that the FDA has granted Fast Track designation for LX201, a silicone matrix ocular implant that steadily releases therapeutic doses of cyclosporine A locally to the eye, to prevent corneal transplant rejection.
Subscribe to our email newsletter
The Fast Track drug development program is designed to promote the development of drugs to treat life-threatening or very serious conditions and requires that the drug demonstrate the potential to address unmet medical needs.
Ulrich Grau, president and CEO of Lux, said: “With this Fast Track designation, we can more rapidly work to provide a much needed therapy to patients. If successful, LX201 would become the first treatment available for the prevention of corneal transplant rejection.”